Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells $813,720.60 in Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Lauren Rusckowski Duprey sold 47,586 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $17.10, for a total transaction of $813,720.60. Following the sale, the insider directly owned 226,057 shares of the company’s stock, valued at approximately $3,865,574.70. This represents a 17.39% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Performance

Shares of NYSE TAK opened at $17.64 on Friday. The company has a quick ratio of 0.62, a current ratio of 1.14 and a debt-to-equity ratio of 0.58. The firm’s 50-day moving average price is $16.57 and its two-hundred day moving average price is $17.14. Takeda Pharmaceutical Co. has a 52-week low of $12.99 and a 52-week high of $18.90. The stock has a market capitalization of $56.53 billion, a P/E ratio of 51.89 and a beta of -0.08.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. The company had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%. As a group, sell-side analysts forecast that Takeda Pharmaceutical Co. will post 0.32 earnings per share for the current year.

Analysts Set New Price Targets

TAK has been the topic of several recent research reports. Zacks Research raised Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Weiss Ratings lowered Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Takeda Pharmaceutical presently has an average rating of “Hold”.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in TAK. Valeo Financial Advisors LLC grew its stake in shares of Takeda Pharmaceutical by 6.0% in the fourth quarter. Valeo Financial Advisors LLC now owns 11,220 shares of the company’s stock worth $175,000 after purchasing an additional 632 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of Takeda Pharmaceutical by 3.8% during the third quarter. Franklin Resources Inc. now owns 19,458 shares of the company’s stock valued at $285,000 after purchasing an additional 713 shares during the period. Abel Hall LLC raised its stake in shares of Takeda Pharmaceutical by 2.3% during the first quarter. Abel Hall LLC now owns 34,099 shares of the company’s stock valued at $632,000 after purchasing an additional 781 shares in the last quarter. Private Trust Co. NA raised its stake in shares of Takeda Pharmaceutical by 84.7% during the fourth quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after purchasing an additional 783 shares in the last quarter. Finally, Checchi Capital Advisers LLC lifted its holdings in Takeda Pharmaceutical by 5.7% in the first quarter. Checchi Capital Advisers LLC now owns 14,591 shares of the company’s stock worth $270,000 after purchasing an additional 786 shares during the period. Institutional investors and hedge funds own 9.17% of the company’s stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.